Patents by Inventor Lumir Hanus

Lumir Hanus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7759526
    Abstract: The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives. It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 20, 2010
    Assignee: Yissum Research Development Company
    Inventors: Raphael Mechoulam, Susana Tchilibon, Ester Fride, Lumir Hanus, Aviva Breuer, Ruth Gallily
  • Publication number: 20080275135
    Abstract: Disclosed are synthetic cannabinoids, namely resorcinol derivatives, which reduce blood pressure without having psychotropic effects. Pharmaceutical compositions for the treatment of high blood pressure related conditions, as well as methods of treating the same utilizing as active agent the compounds of the invention are also disclosed herein. Preferred active compounds are those which bear a long side chain on the C5 position and a terpenoid chain on the C2 position.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 6, 2008
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
    Inventors: Raphael Mechoulam, Yehoshua Maor, Lumir Hanus, Michal Horowitz
  • Patent number: 7214716
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: May 8, 2007
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Publication number: 20050165118
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Application
    Filed: January 27, 2005
    Publication date: July 28, 2005
    Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Patent number: 6903137
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: June 7, 2005
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Patent number: 6864291
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: March 8, 2005
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Publication number: 20030166727
    Abstract: The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity.
    Type: Application
    Filed: January 30, 2003
    Publication date: September 4, 2003
    Inventors: Raphael Mechoulam, Susana Tchilibon, Ester Fride, Lumir Hanus, Aviva Breuer, Ruth Gallily
  • Publication number: 20020173528
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Application
    Filed: April 26, 2002
    Publication date: November 21, 2002
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon